文献速递呼吸道感染呼吸危重症与机械通气

生物标志物指导疑似呼吸机相关性肺炎的抗生素管理(VAPrapid2):随机对照试验及过程评估

Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation.
PubMed 文献 · Lancet Respir Med · 2019-12-03

VAPrapid2 是一项多中心随机对照试验,纳入 210 例临床疑似呼吸机相关性肺炎的机械通气患者,评估支气管肺泡灌洗液 IL-1β 和 IL-8 指导抗生素停用的效果。结论认为快速高敏感性排除试验未能改善抗生素管理,处方文化可能是主要原因。

要点

  • 疑似 VAP 患者中抗生素使用率仍高,生物标志物指导未改善抗生素管理。
  • 支气管肺泡灌洗与氧需求短暂小幅增加相关。

核心结论

  • 在疑似呼吸机相关性肺炎患者中,基于支气管肺泡灌洗液 IL-1β 和 IL-8 的快速排除试验未能改善抗生素管理。
  • 处方文化而非试验性能不佳可能是缺乏效果的原因。

研究设计与样本

  • 多中心、随机对照试验,在英国、苏格兰和北爱尔兰的 17 个国民健康服务体系医院信托的 24 个 ICU 进行。
  • 纳入 18 岁及以上、插管机械通气至少 48 小时、临床疑似呼吸机相关性肺炎的患者。
  • 210 例患者随机分配至生物标志物指导抗生素建议组(n=104)或常规抗生素使用组(n=106)。
  • 主要结局为支气管肺泡灌洗后 7 天内无抗生素天数的分布,按意向性分析。

主要发现

  • 支气管肺泡灌洗与氧需求短暂小幅增加相关。
  • 已建立的处方实践、对支气管肺泡灌洗的抵触以及依赖一系列试验相关流程是影响试验过程的因素。

关键数值与推荐

  • 支气管肺泡灌洗液 IL-1β 和 IL-8 浓度低于先前验证的截断值时,建议临床医生考虑停用抗生素。
  • 呼吸机相关性肺炎通过支气管肺泡灌洗液菌落计数至少 10^4 CFU/mL 确认。

临床怎么用

  • 对于临床疑似呼吸机相关性肺炎的患者,快速生物标志物排除试验未显示能改善抗生素管理。
  • 需关注处方文化对抗生素管理干预效果的影响。

局限性

  • 试验过程受已建立处方实践、对支气管肺泡灌洗的抵触及依赖试验相关流程链等因素影响。
  • 意向性分析排除了生物标志物指导组中一例支气管镜检查前撤回的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ventilator-associated pneumonia is the most common intensive care unit (ICU)-acquired infection, yet accurate diagnosis remains difficult, leading to overuse of antibiotics. Low concentrations of IL-1β and IL-8 in bronchoalveolar lavage fluid have been validated as effective markers for exclusion of ventilator-associated pneumonia. The VAPrapid2 trial aimed to determine whether measurement of bronchoalveolar lavage fluid IL-1β and IL-8 could effectively and safely improve antibiotic stewardship in patients with clinically suspected ventilator-associated pneumonia. METHODS: VAPrapid2 was a multicentre, randomised controlled trial in patients admitted to 24 ICUs from 17 National Health Service hospital trusts across England, Scotland, and Northern Ireland. Patients were screened for eligibility and included if they were 18 years or older, intubated and mechanically ventilated for at least 48 h, and had suspected ventilator-associated pneumonia. Patients were randomly assigned (1:1) to biomarker-guided recommendation on antibiotics (intervention group) or routine use of antibiotics (control group) using a web-based randomisation service hosted by Newcastle Clinical Trials Unit. Patients were randomised using randomly permuted blocks of size four and six and stratified by site, with allocation concealment. Clinicians were masked to patient assignment for an initial period until biomarker results were reported. Bronchoalveolar lavage was done in all patients, with concentrations of IL-1β and IL-8 rapidly determined in bronchoalveolar lavage fluid from patients randomised to the biomarker-based antibiotic recommendation group. If concentrations were below a previously validated cutoff, clinicians were advised that ventilator-associated pneumonia was unlikely and to consider discontinuing antibiotics. Patients in the routine use of antibiotics group received antibiotics according to usual practice at sites. Microbiology was done on bronchoalveolar lavage fluid from all patients and ventilator-associated pneumonia was confirmed by at least 104 colony forming units per mL of bronchoalveolar lavage fluid. The primary outcome was the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage. Data were analysed on an intention-to-treat basis, with an additional per-protocol analysis that excluded patients randomly assigned to the intervention group who defaulted to routine use of antibiotics because of failure to return an adequate biomarker result. An embedded process evaluation assessed factors influencing trial adoption, recruitment, and decision making. This study is registered with ISRCTN, ISRCTN65937227, and ClinicalTrials.gov, NCT01972425. FINDINGS: Between Nov 6, 2013, and Sept 13, 2016, 360 patients were screened for inclusion in the study. 146 patients were ineligible, leaving 214 who were recruited to the study. Four patients were excluded before randomisation, meaning that 210 patients were randomly assigned to biomarker-guided recommendation on antibiotics (n=104) or routine use of antibiotics (n=106). One patient in the biomarker-guided recommendation group was withdrawn by the clinical team before bronchoscopy and so was excluded from the intention-to-treat analysis. We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58). Bronchoalveolar lavage was associated with a small and transient increase in oxygen requirements. Established prescribing practices, reluctance for bronchoalveolar lavage, and dependence on a chain of trial-related procedures emerged as factors that impaired trial processes. INTERPRETATION: Antibiotic use remains high in patients with suspected ventilator-associated pneumonia. Antibiotic stewardship was not improved by a rapid, highly sensitive rule-out test. Prescribing culture, rather than poor test performance, might explain this absence of effect. FUNDING: UK Department of Health and the Wellcome Trust.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Hellyer TP, McAuley DF, Walsh TS, et al. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. Lancet Respir Med. 2019. PMID: 31810865. doi:10.1016/S2213-2600(19)30367-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。